News | March 18, 2026
Zydus, Lupin join forces to expand access to semaglutide in India
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
Indomo’s ClearPen system combines a proprietary self-injection device and microneedle with a modernized triamcinolone acetonide formulation
Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms
DiaMedica said it plans to launch the trial later in 2026
The system also introduces Imaging Scanner Interface 2 (ISI2) capability, enabling direct communication between injector and scanner to improve exam coordination and operational efficiency
Desmopressin Acetate Injection is primarily used to treat central diabetes insipidus, haemophilia A, and von Willebrand disease
The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
Zydus has developed an innovative Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a patient-friendly reusable pen for which the company has exclusive rights
Subscribe To Our Newsletter & Stay Updated
